For research use only
| Cat No. | ABC-TC0578 |
| Product Type | Human Bone Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | LAN-1; LAN1; Lan1 |
LA-N-1, a human neuroblastoma bone marrow metastasis cell line, ideal for studying tumor biology, metastasis, and neuroblastoma-related drug responses.
LA-N-1 is a human neuroblastoma cell line derived from bone marrow metastasis of a 2-year-old male patient with Stage IV neuroblastoma. The cells display semi-adherent growth with neuroblast-like morphology and are suitable for in vitro propagation. They exhibit aneuploid karyotype, express neuroblastoma markers such as N-Myc and GD2, and show stable proliferation over multiple passages. LA-N-1 forms tumors in immunodeficient mice, reflecting its tumorigenic potential. LA-N-1 is widely used for studying tumor biology, metastasis, and neuroblastoma signaling pathways. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | LAN-1; LAN1; Lan1 |
| Species | Human |
| Cat.No | ABC-TC0578 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Semi-adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Bone Cancer Cell Lines |
LA-N-1 provides a reliable model for neuroblastoma research, including metastasis studies, drug response testing, and tumor progression analysis. Its semi-adherent growth and expression of neuroblast-specific markers make it suitable for molecular signaling studies, metastasis modeling, and preclinical drug evaluation. Its stable growth and semi-adherent properties make it suitable for long-term culture and translational studies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
